Key result
Early-stage hypertensive heart disease is linked to higher cardiovascular autoantibodies versus normal cardiac function.
Why the study?
Does autoantibody profiling on a plasmonic nano-gold chip detect early-stage hypertensive heart disease in hypertensive patients?
Observational
Does autoantibody profiling on a plasmonic nano-gold chip detect early-stage hypertensive heart disease in hypertensive patients?
A novel plasmonic nano-gold platform can profile cardiovascular autoantibodies to identify hypertensive patients at risk for early-stage heart failure.
May aid early detection in hypertension; leaves open clinical utility pending prospective validation.
Significance Hypertension affects one in four adults in the United States and is a major risk factor for heart failure. A plasmonic nano-gold platform with excellent reproducibility and sensitivity is developed to address the currently unmet need of profiling circulating cardiovascular autoantibodies in hypertensive patients. We observed that patients with early-stage hypertensive heart diseases displayed a higher level of cardiovascular autoantibodies than hypertensive patients with normal cardiac function. Autoantibodies to troponin I, adrenergic beta-1 receptor, and annexin-A5 could best discriminate hypertensive heart disease. Ultimately, this nanoscience-based platform could be deployed to facilitate screening autoantibodies and identify at-risk patients for early stages of heart failure. Furthermore, this platform could have broad applications in myocarditis, heart transplantation, and other autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Li et al. (2017) conducted an observational in Hypertensive heart disease. Plasmonic nano-gold platform for autoantibody profiling vs. Hypertensive patients with normal cardiac function was evaluated on Level of cardiovascular autoantibodies. A plasmonic nano-gold platform demonstrated that patients with early-stage hypertensive heart disease display higher levels of cardiovascular autoantibodies than those with normal cardiac function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: